Document is current
Any future updates will be listed below
-
Authors
Vavassori, Valentina
Mercuri, Elisabetta
Marcovecchio, Genni E
Castiello, Maria C
Schiroli, Giulia
Albano, Luisa
Margulies, Carrie
Buquicchio, Frank
Fontana, Elena
Beretta, Stefano
Merelli, Ivan
Cappelleri, Andrea
Rancoita, Paola MV
Lougaris, Vassilios
Plebani, Alessandro
Kanariou, Maria
Lankester, Arjan
Ferrua, Francesca
Scanziani, Eugenio
Cotta‐Ramusino, Cecilia
Villa, Anna
Naldini, Luigi https://orcid.org/0000-0002-7835-527X
Genovese, Pietro https://orcid.org/0000-0001-9507-9003
-
Funding
Funding for this research was provided by:
Fondazione Telethon (TIGET‐E3)
Ministero della Salute (GR‐2013‐02358956)
Ministero della Salute (GR‐2016‐02364847)
Ministero della Salute (PE‐2016‐02363691)
Ministero della Salute (E‐Rare‐3 JTC 2017)
Banca d'Italia
Ministero dell'Istruzione, dell'Università e della Ricerca (PRIN 2017 Prot. 20175XHBPN)
Editas Medicine
EU Horizon 2020 Program
Liberal contribution
Louis‐Jeantet Foundation
Jeantet‐Collen Prize for Translational Medicine
- License Information
-
More Information
Article History
Received: 6 October 2020
Revised: 8 December 2020
Accepted: 10 December 2020
First Online: 21 January 2021
Conflict of interest
: LN, PG, GS, and VV are inventors of patent applications on gene editing in HSPC and cell selection owned and managed by the San Raffaele Scientific Institute and the Telethon Foundation, including a patent application on CD40L gene editing shared with Editas Medicine. CM and FB are current employees of Editas Medicine. LN and PG are founders and quota holders of GeneSpire, a startup company aiming to develop gene editing application in HIGM1 and other genetic diseases. All other authors declare no conflict of interests.
